Fox Run Management, L.L.C. Astria Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $588 Million
- Q3 2025
A detailed history of Fox Run Management, L.L.C. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 19,957 shares of ATXS stock, worth $250,859. This represents 0.02% of its overall portfolio holdings.
Number of Shares
19,957Holding current value
$250,859% of portfolio
0.02%Shares
2 transactions
Others Institutions Holding ATXS
# of Institutions
121Shares Held
50.8MCall Options Held
48.8KPut Options Held
55.8K-
Perceptive Advisors LLC New York, NY6.49MShares$81.5 Million0.1% of portfolio
-
Vestal Point Capital, LP New York, NY4.96MShares$62.3 Million1.63% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$51.6 Million5.98% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$44.7 Million5.59% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$44.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $191M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...